Health economic value of an innovation: delimiting the scope and framework of future market entry agreements
Authors:
Open Access
- 29 January 2014
- journal article
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 2 (1)
Abstract
Background and objectives: The objective of our paper is to offer a new, payer-friendly taxonomy of market entry agreements (MEAs) that aims to twin contracts with their methodological designs in an effort to clarify the distinction between contracts that are based on performance and those that are based on demonstrated effect. Methods: Our analysis proceeds in two stages: First, we delimit the scope and framework of pay for performance (P4P) and pay for demonstrated effect (P4E) agreements. Second, we distinguish the methodological designs supporting the implementation of each of these contracts. Results: We elucidate why P4P contracts prevent the payer from funding the true effectiveness of an innovation by expanding on their limitations. These include: 1) the normative nature of comparisons, 2) the impossibility of true effect imputability for each individual, and 3) the use of intermediary outcome measures. We then explore three main criticisms that payers must take into account when reasoning in terms of performance rather than in terms of the product effectiveness. Conclusion: The potential effect that performance-based reimbursements may have on dissociating the components of the cost-effectiveness ratio constitutes an obstacle to a true health economic reasoning. Keywords: risk sharing; pay for performance contract; comparative effectiveness research; cost-effectiveness studies (Published: 23 June 2014) Citation: Journal of Market Access & Health Policy 2014, 2: 24988 - http://dx.doi.org/10.3402/jmahp.v2.24988Keywords
This publication has 8 references indexed in Scilit:
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- Motifs et délais pour l’initiation de la forme injectable à libération prolongée de la rispéridone : enquête auprès de 399 psychiatres françaisL'Encéphale, 2013
- Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug DevelopmentClinical Pharmacology & Therapeutics, 2011
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying conceptsBMC Health Services Research, 2011
- Impact Evaluation in Practice2010
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersBMC Health Services Research, 2010
- Estimating causal effects of treatments in randomized and nonrandomized studies.Journal of Educational Psychology, 1974